Klin Farmakol Farm. 2007;21(3):137-143

Drugs and pregnancy

Ivana Kacířová, Milan Grundmann
Ústav klinické farmakologie FNsP a ZSF Ostravské univerzity, Ostrava

Epidemiologic surveys show that most of pregnant women use at least one medication during pregnancy. Several factors determine whether a drug is teratogenic, including the gestational timing of the exposure, as well as the dose, route and nature of the drug itself. The complex physiologic unit of mother, placenta and fetus undergoes considerable dynamic physiologic changes during pregnancy. Therapeutic drug monitoring during pregnancy aims to better individualize dosing regimens of pregnant women.

Keywords: pharmacokinetics, pregnancy, teratology, therapeutic drug monitoring

Published: January 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kacířová I, Grundmann M. Drugs and pregnancy. Klin Farmakol Farm. 2007;21(3):137-143.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Czeizel AE, Rockenbauer M, Olsen J. Use of antibiotics during pregnancy. Eur J Obstet Gynec Reprod Biol 1998; 81, 1-8 ENTIS (European Network of Teratology Information Services) Newsletter February 1997. Go to original source... Go to PubMed...
    2. Caro-Patón T, Carvajal A, Martín de Diego I et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44: 179-182. Go to original source... Go to PubMed...
    3. Merlob P, Stahl B, Kaplan B. Drug use in pregnancy and breast feeding: the role of the pharmacist. Int J Risk & Safety Med 1998; 11: 45-47.
    4. Peterka M. Vitamín A a nebezpečí vzniku vrozených vad u člověka. Zdrav Nov 1996; 45: 9.
    5. Vrozené vady 1999. Zdravotnická statistika ÚZIS ČR 2000.
    6. Gregor V. Teratogenní rizika v graviditě. Prakt gynekol 2001; 3: 37-40.
    7. Šípek A, Gregor V, Velebil P, Horáček J, Mašátová D, Světnicová K. Výskyt vrozených vad u dětí v potomstvu matek užívajících v I. trimestru gravidity medikaci v České republice v období 1996-2002. Supplementum 2004; 1: 33-41.
    8. Hájek Z, Kulovaný E, Macek M. Základy prenatální diagnostiky. Praha: Avicenum Grada 2000: 33-35.
    9. Straňák Z, Janota J, Melichar J et al. Prenatální diagnostika a léčba kongenitální diafragmatické hernie. Čes Gynek 1998; 5: 377-382.
    10. Jančárková N, Gregor V. Teratogeny v těhotenství. Čes Gynek 2000; 3: 188-194.
    11. Brockelbank JC, Ray WA, Federspiel CF et al. A controlled study of Tennessee Medicaid recipients. Drug prescribing during pregnancy. Am J Obstet Gynecol 1978; 132: 235-244. Go to original source... Go to PubMed...
    12. Bleyer WA, Au WY, Lange WA et al.: Studies on the detection of adverse reactions in the newborn. I. Fetal exposure to maternal mediaction. Jama 1970; 213: 2046-2048. Go to original source... Go to PubMed...
    13. Hill RM. Drugs ingested by pregnant women. Clin Pharmacol Ther 1973; 14: 645-659. Go to original source... Go to PubMed...
    14. Doering PL, Stewart RB. The extent and character of drug consumption during pregnancy. Jama 1978; 239: 843-846. Go to original source...
    15. Lacroix I, Damase-Michel C, Lapeyre-Mestre M et al. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735-1736. Go to original source... Go to PubMed...
    16. Yaffe SJ, Briggs GG. Rizika podávání léčiv v těhotenství. Gynekol po prom březen/duben 2004: 35-40.
    17. Schardein JL. Chemically Induced Birth Defects.3rd ed New York, NY: Marcel Dekker Inc; 2000. Go to original source...
    18. Piper JM, Baum C, Kennedy DL. Prescription drug use before and during pregnancy in a Medicaid population. Am J Obstet Gynecol 1987; 157 (1): 148-156. Go to original source... Go to PubMed...
    19. Grundmann M. Změny farmakokinetiky v těhotenství a jejich klinický význam I. Int Med Prax 2000; 3: 47-48.
    20. Parry E, Shields R, Turnbull A. Transit time in the small intestine in pregnancy. J Obstet Gynecol Br Commonw 1970; 77: 900-901. Go to original source... Go to PubMed...
    21. Pizani BBK, Campbell DM, McGillivray T. Plasma volume in normal pregnancy. J Obstet Gynecol 1973; 80: 884-887. Go to original source...
    22. Dean M. Stock B, Patterson RJ, et al. Serum protein binding of drugs during and after pregnancy in humans. Clin Pharmacol Ther 1980; 28: 253-260. Go to original source... Go to PubMed...
    23. Juchau MR, Mirkin DL, Zachariah PK. Interactions of various 19-nor steroids with human placental microsomal cytochrome P-450. Chem Biol Interact 1976; 15 (4): 337-347. Go to original source... Go to PubMed...
    24. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43 (8): 487-514. Go to original source... Go to PubMed...
    25. Dancis J, Braverman N, Lind J. Plasma protein synthesis in the human fetus and placenta. J Clin Invest 1957; 36: 398-404. Go to original source... Go to PubMed...
    26. Pelkonen O. Drug metabolism in the human fetal liver relationship to fetal age. Arch Int Pharmacodyn Ther 1973; 202 (2): 281-287.
    27. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed Williams & Wilkins, 2005.
    28. Koucký M., ,Banální" léky v těhotenství. Moderní gynekol a porod 2004; 2: 167-173.
    29. Koucký M, Čepický P. Farmakoterapie v těhotenství. Moderní gynekol a porod 2003; 2: 278-284.
    30. Hořínová V. Farmakoterapie v těhotenství z pohledu klinického genetika. Moderní gynekol a porod 2004; 2: 156-166.
    31. Maňáková E. Komentář k článku. Gynekol po prom březen/duben 2004: 41-42.
    32. Kučera J. Populační teratologie. Praha Avicenum 1989.
    33. Grundmann M. Změny farmakokinetiky v těhotenství a jejich klinický význam II. Int Med Prax 2000; 4: 43-44.
    34. Pennell PB. Pregnancy in women who have epilepsy. Neurol Clin 22: 799-820. Go to PubMed...
    35. Loebstein R, Koren G. Clinical Relevance of Therapeutic Drug Monitoring During Pregnancy. Ther Drug Monit 2002; 1: 15-22. Go to original source... Go to PubMed...
    36. Anderson GD. Pregnancy-Induced Changes in Pharmacokinetics. Clin Pharmacokinet 2005; 44 (10): 989-1008. Go to original source... Go to PubMed...
    37. Dawes M, Chowienczyk PJ. Pharmacokinetics in pregnancy. Best Practice&Research Clinical Obstet and Gynecol 2001; 6: 819-826. Go to original source... Go to PubMed...
    38. Diav-Citrin O, Koren G. Human Teratogens: A critical evaluation. The Motherisk program. www.nvp-volumes.org,1998.
    39. Scialli AR. Labeling medications for use in pregnancy. www.nvp-volumes.org, 2003.
    40. Anděl T, Vašut K. Problematika bezpečnosti léčiv v těhotenství. www.safebryo.cz, 2005.
    41. Polifka JE, Friedman JM. Medical genetics: 1. Clinical teratology in the age of genomics. CMAJ 2002; 167 (3): 265-273. Go to PubMed...
    42. Pizani BBK, Campbell DM, McGillivray T. Plasma volume in normal pregnancy. J Obstet Gynecol 1973; 80: 884-887. Go to original source...
    43. Meadows M. Pregnancy and the Drug Dilemma. FDA Consumer magazine 2001. www.fda. gov, 2001. Go to original source...
    44. Palahniuk RJ, Shnider SM, Eger EI. Pregnancy decreases the requirement for inhaled anesthetic agents. Anesthesiology 1974; 41: 82-83. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.